Appendix E Table 10. Quality of Life Results in Studies of Treatment for Small AAA (KQs 4 and 5)

| **Intervention** | **Study** | **QOL****Screening** | **Time Period** | **Treatment Group** | **N****Analyzed** | **QOL Scores, Mean (SD)*¶*** | **Mean Difference (95% CI), P-Value** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Open surgery vs. surveillance | Forbes 1998127UKSAT | MOS subscale\* | Baseline | IG | 480 | Physical function: 64.2 (30.7)Mental health: 80.2 (17.2) | Physical function: -2.3 (-6.0 to 1.5); NRMental health: 0.7 (-1.5 to 2.8); NR |
| CG | 512 | Physical function: 66.5 (29.3)Mental health: 79.5 (17.0) |
| 12 months post- randomization | IG | 429 | Physical function: 62.1 (29.9)Mental health: 81.7 (17.9)*Mean difference from BL:*Physical function: -3.5 (-6.1 to -0.8)Mental health: 0 (-1.5 to 1.5) | Physical function: 1.7 (-2.3 to 5.7)Mental health: 2.1 (-0.4 to 4.5) |
| CG | 436 | Physical function: 60.3 (30.2)Mental health: 79.6 (18.6)*Mean difference from BL:*Physical function: -6.2 (-8.8 to -3.7)Mental health: 0 (1.7 to 1.8) |
| EVAR vs. surveillance | De Rango 2011122CAESAR | SF-36\* | Baseline through 6 months post- randomization | IG | 173 | *Mean difference (95% CI) from BL:*Overall QOL: 4.6 (2.3 to 7)Physical functioning: -0.6 (-3.7 to 2.4)Mental health: 5.2 (2.8 to 7.5) | *IG vs. CG*Overall QOL: 5.4 (2.1 to 8.8); p=0.002Physical function: 3.8 (0.5 to 7.2); p=0.02Mental health: 6.0 (2.7 to 9.3); p=0.0005 |
| CG | 166 | *Mean difference (95% CI) from BL:*Overall QOL: -0.8 (-3.2 to 1.6)Physical functioning: -4.3 (-7.3 to -1.2)Mental health: -0.8 (-3.2 to 1.5) |
| Baseline through end of followup§ | IG | 173 | *Mean difference (95% CI) from BL:*Overall QOL: 4.6 (2.3 to 7)Physical functioning: -0.6 (-3.7 to 2.4)Mental health: 5.2 (2.8 to 7.5) | *IG vs. CG*Overall QOL: 2.4 (-1.7 to 6.6); p=0.25Physical function: 1.5 (-2.6 to 5.5); p=0.48Mental health: 2.0 (-2.4 to 6.4); p=0.38 |
| CG | 166 | *Mean difference (95% CI) from BL:*Overall QOL: -6.3 (-9.3 to -3.4)║Physical functioning: -8.2 (-12.0 to -4.4)Mental health: 4.8 (-7.9 to -1.7)║ |
| Eisenstein, 2013124PIVOTAL | EQ-5D# | Baseline | IG | 351 | *Utility score: 0.805 (0.1)*\*\**Visual analog scale: 77.8 (14)* | NR |
| CG | 350 | *Utility score: 0.783 (0.2)*\*\**Visual analog scale: 78.2 (15)* |
| 24 months post-baseline | IG | 205 | *Utility score: 0.797 (0.2)*\*\**Visual analog scale: 76.2 (17)* |
| CG | 197 | *Utility score: 0.817 (0.2)*\*\**Visual analog scale: 76.5 (18)* |
| Pharmacotherapy vs. surveillance | Lindholt 1999142 | ScreenQL\*† | Baseline through 2 y | IG | 30 | NR | Overall QOL: -5.83 (6.2)‡; p=0.05Emotional domain: -0.35 (2.1)‡; p=0.59 Health perception: -1.39 (2.98)‡; p=0.13 |
| CG | 24 | NR | Overall QOL: -1.70 (5.5)‡; p=0.07Emotional domain: 0.00 (2.0)‡; p=0.69 Health perception: -0.38 (2.10)‡; p=0.30 |
| PAT Investigators, 2002164PAT | SF-36\* | Baseline | IG | 276 | Physical function: 70.8 (23.9)Mental health: 78.9 (17.3) | Physical function: p=0.11 Mental health: p=0.45 |
| CG | 272 | Physical function: 74.1 (24.0)Mental health: 77.8 (17.9) |
| 1 month post- randomization | IG | 276 | Physical function: 68.9 (18.9)Mental health: 78.9 (17.6) | Physical function: p=0.006 Mental health: p=0.58 |
| CG | 272 | Physical function: 74.4 (23.8)Mental health: 78.3 (17.5) |

\*Lower score denotes poorer status.

†A validated generic and global QOL questionnaire with 24 items evaluating six categories: general QOL, emotional health, physical health, psychosomatic distress, social and family functions, and marriage.

‡Mean (SD); change from baseline in each group, not IG vs. CG.

§Mean, 3 years from baseline (SD, 1.2 years).

║p<0.01.

*¶*Only summary scores reported here. For complete subscales please see full text.

# Utility score uses responses to the five dimensions (Mobility, Self-care, Usual activity, Pain/discomfort, Anxious/depressed) to compute a value on a scale of -0.54 to 1.00; higher utility score indicates a better quality of life and a negative value indicates a health state worse than death that can be used to quality-adjust study patient survival time. The final EQ-5D element, visual analog score (VAS), provides a one-question assessment of an individual’s quality of life and ranges from 0 to 100, with a higher score indicating a better quality of life.

\*\*Utility score N analyzed by group and followup: Baseline IG n = 348, CG n = 349; 24-month postbaseline IG n = 203, CG n = 191.

**Abbreviations:** BL = baseline; CAESAR *=* Comparison of Surveillance Versus Aortic Endografting for Small Aneurysm Repair; CG = control group; EVAR = endovascular aneurysm repair; IG = intervention group; MOS = Medical Outcomes Study; NR = not reported; PAT = Propanolol Aneurysm Trial; QOL = quality of life; SF-36 = Short-Form 36-Item Health Survey; UKSAT = UK Small Aneurysm Trial.